PHARMA HOLDINGS AS
🇳🇴Norway
Clinical Trials
7
Active:1
Completed:3
Trial Phases
2 Phases
Phase 1:3
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (57.1%)Phase 1
3 (42.9%)Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus
Phase 2
Completed
- Conditions
- Nasal Decolonization of Staphylococcus Aureus
- Interventions
- Drug: Vehicle gel, 4 + 4 applications or 4 + 2 applications
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Pharma Holdings AS
- Target Recruit Count
- 27
- Registration Number
- NCT05889351
- Locations
- 🇸🇪
ClinSmart Sweden AB, Uppsala, Sweden
Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Pharma Holdings AS
- Target Recruit Count
- 60
- Registration Number
- NCT04854928
- Locations
- 🇸🇪
ClinSmart Sweden AB, Uppsala, Sweden
A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus
Phase 1
Completed
- Conditions
- Nasal Decolonization of Staphylococcus Aureus
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Pharma Holdings AS
- Target Recruit Count
- 15
- Registration Number
- NCT04767321
- Locations
- 🇸🇪
ClinSmart Sweden AB, Uppsala, Sweden
LTX-109 as Treatment for Hidradenitis Suppurativa
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Pharma Holdings AS
- Target Recruit Count
- 11
- Registration Number
- NCT04756336
- Locations
- 🇳🇴
University Hospital of North Norway, Tromsø, Norway
News
No news found